Island Pharmaceuticals Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported net loss was AUD 2.61 million compared to AUD 2.13 million a year ago. Basic loss per share from continuing operations was AUD 0.0322 compared to AUD 0.1141 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 AUD | +26.98% | +29.03% | -15.79% |
05-08 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
04-16 | Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.79% | 4.85M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ILA Stock
- News Island Pharmaceuticals Limited
- Island Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022